The Food and Drug Administration will allow a new device to be marketed as a treatment for dry age-related macular degeneration. When you purchase through links on our site, we may earn an affiliate ...
Those treated with the device could also read, on average, five lines of a vision chart; some participants could not even see the chart before their surgery. The trial, with 38 patients in 17 hospital ...
Those treated with the device could also read, on average, five lines of a vision chart; some participants could not even see the chart before their surgery. The trial, with 38 patients in 17 hospital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback